MYR Pharmaceuticals launches HEPCLUDEX® in Germany\, France and Austria

BAD HOMBURG\, Germany\, Sept. 17\, 2020 /PRNewswire/ -- MYR Pharmaceuticals\, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D\, is pleased to announce that HEPCLUDEX® (bulevirtide) has successfully...